Top Cited Articles

We are delighted to share the 2019 impact factor for the Journal for ImmunoTherapy of Cancer of 10.252 (Journal Citation Reports, Clarivate Analytics), which ranked 16/244 in the Oncology category and 10/158 in the Immunology category.

The quality and impact of our journals are dependent on many different measures. We’ve provided here some of those metrics for Journal for ImmunoTherapy of Cancer, to reflect the latest 2019 data, that remain important to our authors. We’ve also listed our top most cited articles from each of the last two years, free to read.

2019

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
FEBRUARY 2019 10.1186/s40425-019-0527-y

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
APRIL 2019 10.1186/s40425-019-0585-1

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
APRIL 2019 10.1186/s40425-019-0577-1

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
JANUARY 2019 10.1186/s40425-018-0478-8

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
MAY 2019 10.1186/s40425-019-0617-x

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
JULY 2019 10.1186/s40425-019-0662-5

Exploring the emerging role of the microbiome in cancer immunotherapy
APRIL 2019 10.1186/s40425-019-0574-4

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
JULY 2019 10.1186/s40425-019-0659-0

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
JUNE 2019 10.1186/s40425-019-0623-z

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
APRIL 2019 10.1186/s40425-019-0579-z

2018

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
JANUARY 2018 10.1186/s40425-018-0316-z

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
JANUARY 2018 10.1186/s40425-017-0310-x

Cytokine release syndrome
JUNE 2018 10.1186/s40425-018-0343-9

Targeting adenosine for cancer immunotherapy
JUNE 2018 10.1186/s40425-018-0360-8

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
MAY 2018 10.1186/s40425-018-0349-3

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
JANUARY 2018 10.1186/s40425-018-0315-0

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
JULY 2018 10.1186/s40425-018-0383-1

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
APRIL 2018 10.1186/s40425-018-0336-8

Targeting the TGF beta pathway with galunisertib, a TGF beta RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
JUNE 2018 10.1186/s40425-018-0356-4

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
MARCH 2018 10.1186/s40425-018-0328-8

Journal Metrics:

Speed
Days to first decision: 44
Days from acceptance to publication: 21

Impact
2 year Impact Factor (JCR): 9.913
SciMago Journal Rank (SJR): 4.194
Eigenfactor: 0.01603
Citescore: 8.6

Reach
Altmetric score: 5,976